Condition (MeSH)
Plasmablastic Lymphoma
ClinicalTrials.gov lists 17 trials for Plasmablastic Lymphoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 17 trials are tagged with Plasmablastic Lymphoma itself; the rest are tagged with a narrower condition beneath it.
When did Plasmablastic Lymphoma trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 2 |
| 2018 | 1 |
| 2016 | 2 |
| 2015 | 1 |
| 2010 | 2 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Plasmablastic Lymphoma trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Observational | 2 |
How many Plasmablastic Lymphoma trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 7 |
| Active, not recruiting | 2 |
| Completed | 3 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Plasmablastic Lymphoma trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| AIDS Malignancy Consortium | 3 |
| Schrödinger, Inc. | 1 |
| Xencor, Inc. | 1 |
Which drugs are being tested for Plasmablastic Lymphoma? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 5 |
| Prednisone | 5 |
| RITUXIMAB | 4 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Doxorubicine | 5 |
| Etoposid | 5 |
| Vincristina | 5 |
| Cytarabine IT | 2 |
| Positron Emission Tomography (PET) | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Plasmablastic Lymphoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Febrile neutropenia | 39 | 2 |
| Febrile Neutropenia | 26 | 2 |
| Anemia | 22 | 3 |
| Neutrophil Count Decreased | 21 | 1 |
| White blood cell decreased | 20 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Plasmablastic Lymphoma? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma. | Journal for immunotherapy of cancer | 2023 | Yes |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Plasmablastic lymphoma | 289666 | Exact | Orphadata Science knowledge files, Product 1 |
| Plasmablastic lymphoma | 289666 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.